A pharmaceutical firm operates in a space where emerging gen…
A pharmaceutical firm operates in a space where emerging gene-therapy startups threaten to make traditional chemical drugs obsolete. Despite this, the firm remains the market leader because their manufacturing yield is double that of any competitor. This superior yield is the result of a “black box” process—master chemists make adjustments based on tacit intuition that the firm’s own engineers have been unable to codify. Apply two different class frameworks to identify their generic strategy and the degree of advantage they hold. Then, identify one specific way the ‘causal ambiguity’ of their yield process could actually become a Core Rigidity (a disadvantage) (incorporate the ‘Lexington’ regulatory limitation here) if the market for this specific condition shifts suddenly. Should they expect persistence? Why?